Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG006 and ZG005 in advanced SCLC or NEC
NCT07038096Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig, nilvanstomig in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), sponsored by Zelgen. Started Sep 2025; status: recruiting.
02
Drugs
alveltamignilvanstomig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07038096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038096.